Technology makes a difference.
Increasing bioavailability while mitigating side effects is the Holy Grail of many research teams. With the use of Biotts technology, this goal becomes attainable. The development of deep penetrating transdermal systems, selectively acting on pathologically changed tissues allows for achieving a stronger therapeutic effect, while significantly increasing patient comfort and reducing the costs of treatment.


MTC-Y is an original, universal, transdermal carrier of active substances, which increases their bioavailability. The mixture of excipients constituting the carrier of MTC-Y consists of components that ensure a simultaneous introduction of several active substances of different character and physiochemical properties into the body. Additionally, each of them can be introduced simultaneously in different polymorphic varieties, which makes it possible to create preparations with a modified profile of activity.

Thanks to the unique properties of the system, it is possible to increase the bioavailability of active substances up to 10 times and enable active substances to penetrate through skin barriers up to several centimetres. Thanks to the unique formula, it is possible to reduce the doses of substances and at the same time to intensify their action. The effect is the acceleration of treatment with reduced side effects. The unique MTC-Y Biotts system enables the transport of one to several active substances, thanks to which it is possible to design multi-component drugs. MTC-Y carrier is biocompatible with the human skin and non-toxic.

How it works:

Properties of the technology

Design of multi-component drugs

Therapeutic dose reduction

Up to 10 times higher bioavailability

Penetration through the skin barriers to soft tissues and bones

Modified API release profile

Simple and quick modification of formulas

Reduction of side effects up to 5 times

Simple implementation


MTS-X is an original molecular transport system based on non-aggressive molecules of natural origin. The MTS-X system enables the production of any formula of drugs, substances, molecules or vitamins, especially insoluble substances, increasing their bioavailability by increasing the surface of their release. The production technology based on safe, organism-neutral particles allows for transport of any active substance without its aggregation. With the use of MTS-X, we are able to increase the bioavailability of any drug or vitamin up to several times, while reducing toxicity and undesirable effects.

Traditional technology of connecting API to the carrier:

Diagram of Biotts MTS-X technology of API connection to the carrier:

Properties of the technology

Protection of APIs against harmful external impacts

Reducing the adverse effect of API aggregation

Increased bioavailability

Use of carrier molecules neutral to the human body

Modified API release profile

Simple and quick modification of formulas

Reduction of side effects

Simple implementation

Business model

Thanks to the unique technologies of Biotts, we are able to quickly and easily implement proprietary technologies for various therapeutic areas without the need to modify production lines.
The combination of Biotts technology with the existing market solutions, formulas or API creates a unique and unrepeatable quality, which is protected by the Biotts patent cloud, which secures the products of our partners.

Therapeutic areas








Tissue regeneration

Plastic surgery




Customers of technology

Pharmaceutical companies

Chemical companies

Manufacturers of medicines and medical devices

Manufacturers of dietary supplements

Cosmetics manufacturers

Food producers

Manufacturers of veterinary medicines